Your AI-Trained Oncology Knowledge Connection!
According to results from the phase III ASCEND-4 trial, ceritinib (Zykadia) improved progression-free survival (PFS) compared with standard chemotherapy as a first-line treatment for patients with <em>ALK</em>-positive non–small cell lung cancer (NSCLC)
Bruce Cheson, MD, outlines the treatment choices for each of the 3 patient categories of CLL, noting that, regardless of the treatment, “a clinical trial is always the preferred option.”
The PDGFRα antagonist olaratumab has been recommended approval by The Committee for Medicinal Products for Human Use (CHMP) for use in combination with doxorubicin for patients with advanced soft tissue sarcoma (STS) who are not good candidates for radiotherapy or surgery.
According to findings of a recent study, Induction therapy with the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) effectively induced complete remissions (CRs) for nearly three-fourths of patients with relapsed or refractory Hodgkin lymphoma prior to autologous stem-cell transplantation (ASCT)
Chau T. Dang, MD discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
Goals of "Project Impact: A Campaign to Defeat Pediatric Brain Tumors" include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.
As therapeutic approaches with more efficacy and less toxicity are still highly needed, researchers are currently working to identify new targets in the MB field.
Despite some surgical advancements in recurrent glioblastoma, significant progress and a move toward a more personalized approach is still needed, said Jennifer Moliterno Gunel, MD.
Based on findings from the phase III TOURMALINE-MM1 study, the Committee for Medicinal Products for Human Use (CHMP) has recommended a conditional approval for ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the company developing the PARP inhibitor, Tesaro, has announced.
The European Commission (EC) has granted its approval for lenvatinib (Kisplyx; EU) in combination with everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy.
To more effectively treat patients with triple negative breast cancer (TNBC), a greater understanding of the disease must first be obtained, said Angela DeMichele, MD, professor of medicine and epidemiology, breast cancer oncologist, University of Pennsylvania.
According to findings of a recent study, obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer (CRC), compared with those without any history of disease.
According to an analysis published in Cancer1, vaginal brachytherapy (VB) has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.
Results from the phase Ib M13-365 study showed combining the BCL-2 inhibitor venetoclax (Venclexta) with the anti-CD20 agent rituximab (Rituxan) led to objective responses in 86% of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
About one quarter of patients (26%) with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance, according to Ju Dong Yang, MD, MSc, at the 10th Annual Conference of the International Liver Cancer Association (ILCA).
Researchers are further exploring the possibility of using an immunotherapeutic vaccinia virus to treat advanced hepatocellular carcinoma (HCC), according to Ghassan K. Abou-Alfa, MD.
Though a new generation of drugs has proved highly effective against the hepatitis C virus (HCV), a leading risk factor for liver cancer in the United States, there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma (HCC) who already have responded to curative treatment.
Though the current standard of care when treating muscle-invasive bladder cancer calls for neoadjuvant chemotherapy followed by radical cystectomy, the procedure is associated with a fair amount of morbidity and is not suggested lightly, according to Stanley Yap, MD.
Cell cycle progression (CCP) and homologous recombination deficiency (HRD) may be linked to bladder cancer recurrences and pathologic complete responses, according to Hristos Kaimakliotis, MD.
Merck, the manufacturer of pembrolizumab (Keytruda), has announced the FDA has granted priority review to a supplemental biologics license application (sBLA) for the PD-1 inhibitor as a first-line treatment for patients with PD-L1-positive non-small cell lung cancer (NSCLC).
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it. It was formed by 4 urology practices merging to build a main campus that houses the cancer center and radiation therapy center.
Undergoing surgery to prevent ovarian cancer should depend on familial history, as well as age, according to Maurie Markman, MD.
The upcoming HALO 3013 is the first-ever biomarker-driven trial in pancreatic adenocarcinoma, and could potentially change the treatment paradigm for the disease.
The differentiation between squamous and adenocarcinomas in GI cancer could revolutionize the disease's treatment paradigm, according to John Marshall, MD.
A multicenter trial taking place in Germany seeks to quantify the quality of life for patients with metastatic pancreatic cancer undergoing a combination of nab-paclitaxel and gemcitabine.
<div>The developer of neratinib, Puma Biotechnology, has announced the European Medicines Agency (EMA) has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab (Herceptin).</div>
